ID: MRFR/Pharma/2061-HCR | 72 Pages | Published By Kinjoll Dey on March 2023
The Pediatric Healthcare Market will obtain a valuation of USD 63.6 billion and a CAGR of 4.1 % in the forecast period.
$63.6 Billion
4.1%
North America
2020-2027
Pediatric Healthcare Market Overview
The Pediatric Healthcare Market will obtain a valuation of USD 63.6 billion and a CAGR of 4.1 % in the forecast period.Â
Short-term disorders in children due to respiratory or ocular infections and common gastrointestinal illnesses with diarrhea and injury. Growing lifestyle changes has raised concern for such diseases are driving the market. Temporary and chronic diseases like cerebral palsy, diabetes, asthma and allergies, obesity, and other neurological problems lead to chronic sickness. These are demanding better treatment for Pediatric Healthcare Market.
The rise in the number of deaths due to the transmission of viral infections and malnutrition is driving the pediatric healthcare market globally. The increased rate of research activities and technological developments in children’s health drives the market. The industrial players’ concern for new products launched for pediatric patients, the raise of government initiatives, and public awareness are enhancing the market. The development of pediatric treatments and improvements in healthcare infrastructure set wide opportunities for the global pediatric healthcare market in the forecast period.
Middle East and Africa Pediatric Healthcare Market Segments: Â
Middle East and Africa Pediatric healthcare Market has been segmented on the basis of type of diseases which comprise Short term diseases, chronic diseases, and others. On the basis of Therapeutics which comprise cardiology, allergy and immunology, gastroenterology, infectious disease, and others. On the basis of treatment, it segmented into medication, surgery, and others
 Regional Analysis of Pediatric healthcare Market:      Â
Considering the scenario of the Middle East and Africa market, UAE region is believed to be the largest market for Middle-East and Africa Pediatric healthcare. Moreover, Saudi Arabia market is also growing and second largest market for pediatric healthcare. On the other hand, Egypt market is expected to grow at the steady pace in the Middle-East and Pediatric healthcare during the forecasted period. Rest of the Middle East and Africa region is likely to have a limited but steady growth in the market.
Middle East and Africa Pediatric healthcare Market by Treatment
Key Players for Middle East and Africa Pediatric healthcare Market:Â Â
Some of the key players in this market are: Novartis AG (Switzerland), AstraZeneca (UK), Janssen Global Services, LLC (Belgium), Eli Lilly and Company (US), Bristol-Myers Squibb Company (US), AMMT (Dubai), King Faisal Specialist Hospital and Research Centre (Saudi Arabia), VPS Healthcare (UAE)
The report for Middle East and Africa Pediatric healthcare Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
Study objectives of Pediatric healthcare Market:
In May 2022
Summus Global, a global virtual specialist platform, announced a collaboration with Boston Children's Hospital for virtual care for families worldwide. This collaboration will let the company work with the innovation team at Boston Children's. This will support innovative ways for specialist expertise to reach patients and families worldwide.
Additionally, the company will support Boston Children's Online Second Opinion Program, to help more families access Boston Children's world-class expertise. The program has supported many families with their care journeys.
In May 2022
Children's Hospital Colorado has declared a partnership with Guild to provide accessible education opportunities to team members. The new benefit is additional to fulfill the promise of team members by investing and supporting their potential. It is much more than an education benefit program. It will provide a growth chance, advancement, and discovery at every level.Â
Intended Audience
Report Attribute/Metric | Details |
---|---|
Market Size | USD 63.6 Billion |
CAGR | 4.1% (2016-2022) |
Base Year | 2019 |
Forecast Period | 2020-2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type Of Diseases, Therapeutics and Treatment |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Novartis AG (Switzerland), AstraZeneca (UK), Janssen Global Services, LLC (Belgium), Eli Lilly and Company (US), Bristol-Myers Squibb Company (US), AMMT (Dubai), King Faisal Specialist Hospital and Research Centre (Saudi Arabia), VPS Healthcare (UAE) |
Key Market Opportunities | Technological advancement and government initiatives to improve healthcare sector |
Key Market Drivers | Increasing short term & chronic diseases |
Global Middle East and Africa Pediatric Healthcare Market is projected to grow at a 4.1% CAGR between 2017-2023.
The UAE is predicted to dominate Middle East and Africa Pediatric Healthcare Market.
Global Middle East and Africa Pediatric Healthcare Market is predicted to touch USD 63.6 billion by 2023.
Developing healthcare infrastructure and government initiatives to improve healthcare is boosting market growth.
Key players profiled in the Middle East and Africa Pediatric Healthcare Market include Siemens (U.S.), I-SENS, Inc. (South Korea), Abbott (U.S.), Bayer AG (Germany), Medtronic Plc. (U.S.), and Hoffmann-La Roche AG (Germany).